
Vildagliptin (50mg)
Active composition
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Medical applications
Justmet V 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the body's incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP. These hormones increase insulin secretion from pancreatic beta cells and decrease glucagon release from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Justmet V 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin when monotherapy is insufficient. It is generally well tolerated, with a low risk of weight gain and hypoglycemia compared to other antidiabetic drugs. Common adverse effects may include headache, nasopharyngitis, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Justmet V 50 Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modification.
Pyrrolidine-carbonitrile derivative
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Justmet V 50 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Justmet V 50 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Justmet V 50 Tablet is safe to use in patients with kidney disease. No dose adjustment of Justmet V 50 Tablet is recommended. However, in patients with moderate to severe kidney disease, dose adjustment may be required. Consult with your doctor.
Exercise Caution
Justmet V 50 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Justmet V 50 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Justmet V 50 Tablet

Vildagliptin (50mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Medical applications
Justmet V 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the body's incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP. These hormones increase insulin secretion from pancreatic beta cells and decrease glucagon release from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Justmet V 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin when monotherapy is insufficient. It is generally well tolerated, with a low risk of weight gain and hypoglycemia compared to other antidiabetic drugs. Common adverse effects may include headache, nasopharyngitis, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Justmet V 50 Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modification.
Pyrrolidine-carbonitrile derivative
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Justmet V 50 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Justmet V 50 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Justmet V 50 Tablet is safe to use in patients with kidney disease. No dose adjustment of Justmet V 50 Tablet is recommended. However, in patients with moderate to severe kidney disease, dose adjustment may be required. Consult with your doctor.
Exercise Caution
Justmet V 50 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Justmet V 50 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Justmet V 50 Tablet













